School of Laboratory Medicine, Weifang Medical University, Weifang, 261053, Shandong, China.
Hum Cell. 2022 Sep;35(5):1346-1354. doi: 10.1007/s13577-022-00729-x. Epub 2022 Jun 3.
Prostate cancer is the most common malignancy of the male genitourinary system and is one of the leading causes of male cancer death. The P2X7 receptor is an important member of purine receptor family. It is a gated ion channel with adenosine triphosphate (ATP) as the ligand, which exists in a variety of immune tissues and cells and can be involved in tumorigenesis and tumor progression. Studies have shown that the P2X7 receptor is abnormally expressed in prostate cancer, and is related to the level of prostate-specific antigen, P2X7 receptor may be an early biomarker of prostate cancer. The P2X7 receptor is essential in the occurrence and development of prostate cancer. The P2X7 receptor mainly affects the invasion and metastasis of prostate cancer cells through epithelial mesenchymal transition/invasion-related genes and the PI3K/AKT and ERK1/2 signaling pathways. The P2X7 receptor could be a promising therapeutic target for prostate cancer.
前列腺癌是男性泌尿生殖系统最常见的恶性肿瘤，也是男性癌症死亡的主要原因之一。P2X7 受体是嘌呤受体家族的重要成员。它是一种由三磷酸腺苷（ATP）作为配体的门控离子通道，存在于多种免疫组织和细胞中，可参与肿瘤的发生和发展。研究表明，P2X7 受体在前列腺癌中异常表达，与前列腺特异性抗原水平有关，P2X7 受体可能是前列腺癌的早期生物标志物。P2X7 受体在前列腺癌的发生发展中起关键作用。P2X7 受体主要通过上皮间质转化/侵袭相关基因以及 PI3K/AKT 和 ERK1/2 信号通路影响前列腺癌细胞的侵袭和转移。P2X7 受体可能成为前列腺癌有前途的治疗靶点。
